Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants
| Autor: | Daniele Pastori, Gregory Y.H. Lip, Alessio Farcomeni, Francesco Del Sole, Angela Sciacqua, Francesco Perticone, Rossella Marcucci, Elisa Grifoni, Pasquale Pignatelli, Francesco Violi, Mirella Saliola, Marco Antonio Casciaro, Danilo Menichelli, Francesco Cribari, Alberto Paladino, Rony Gingis, Marta Novo, Vittoria Cammisotto, Cristina Nocella, Simona Bartimoccia, Roberto Carnevale, Tiziana Di Stefano, Patrizia Iannucci, Elio Sabbatini, Luigi Anastasio, Joseph Tassone Eliezer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
03 medical and health sciences
0302 clinical medicine Multidisciplinary 030220 oncology & carcinogenesis Medicine and Dentistry lcsh:R858-859.7 030204 cardiovascular system & hematology lcsh:Computer applications to medicine. Medical informatics lcsh:Science (General) Settore SECS-S/01 - Statistica lcsh:Q1-390 |
| Zdroj: | Data in Brief Data in Brief, Vol 17, Iss, Pp 830-836 (2018) |
| Popis: | This article contains the data showing the different characteristics of atrial fibrillation (AF) patients treated with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) screened for the presence of liver fibrosis (LF) and followed to record the occurrence of bleeding and cardiovascular events (CVEs). A detailed description of major and minor bleedings is provided according to anticoagulant treatment (VKAs vs. NOACs) and to the presence of LF. Data here reported also show a higher incidence rate of CVEs in VKA-treated patients, but not in those on NOACs. The data are supplemental to our original research article titled “Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonists oral anticoagulants” (Pastori et al., 2018) [1]. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|